StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX)

StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research note released on Monday. The brokerage issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Trading Down 18.3 %

Shares of Brooklyn ImmunoTherapeutics stock opened at $0.26 on Monday. The company has a fifty day moving average price of $0.35 and a 200 day moving average price of $0.94. Brooklyn ImmunoTherapeutics has a twelve month low of $0.17 and a twelve month high of $10.10. The stock has a market cap of $15.52 million, a price-to-earnings ratio of -0.12 and a beta of 4.61.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.